

Authors' reply: In our study we found that recent severe life events were associated with increased salivary cortisol but that depression was not. This is incompatible with the widely held theory that stress predisposes to depression through its effects on the hypothalamic–pituitary–adrenal (HPA) axis. Dr Moore hopes that those with more severe depression may have shown evidence of cortisol hypersecretion. Unfortunately for the stress–HPA theory of depression there is no such evidence – not even in the 9 out of 94 cases with ICD–10 severe depression. The median 23.00 h cortisol levels are identical for the non-depressed subjects and those with depression at all levels of ICD–10 severity. For the 09.00 h cortisol levels, the ‘severe depression’ group median is 7.5 compared with 7.0 for the controls, with interquartile ranges of 5.75 and 5 respectively (i.e. almost total overlap between the groups).

Although it has become dogma that cortisol secretion is increased in depression, increased cortisol secretion is only reliably recorded in severe and often psychotic depression in hospital in-patients. We suggest that this reflects a primary disorder of the HPA in patients with bipolar and psychotic illness, which is unlikely to be connected with psychosocial stress. Our findings indicate that most depression occurs with normal or slightly reduced cortisol secretion and this finding is already present in the literature. For example, Stokes *et al* (1984) found that only 15–20% of subjects with depression in the community had elevated plasma cortisol concentrations. It seems inescapable that sustained hypercortisolaemia is not how social adversity causes depression. However, there is evidence from our study that depression is associated with sensitisation of the HPA axis to chronic stress. Chronic stress occurred in many non-depressed subjects but had no effect on cortisol, whereas in subjects with depression cortisol was increased in those who were chronically stressed. Therefore, increased cortisol in those with chronic stress is due to the depression and not vice versa; it is a marker for brain vulnerability to depression and not the proximal cause of the depressed state. As the findings of Maes *et al* (1994) suggest, the profound stress of admission to a psychiatric hospital may be the factor that induces hypercortisolaemia in hospital studies of depression, since cortisol was not increased in community patients with equal levels of depression. Similarly, as Garland

importantly points out, degree of stress may be the key factor in determining physical morbidity and mortality associated with depression; the interaction of stress with being depressed may be all-important in determining the physical and psychiatric outcome of depression.

Contrary to Garland's assertion, the dexfenfluramine results were not ‘negative’; we found enhanced responses in the ‘depressed’ group. Perhaps he regards the failure to observe blunting in depression as a negative result. But our study is arguably the largest and best-controlled ever performed. Furthermore, exaggerated 5-HT_{2C} responses in depression have been observed in studies using 5-hydroxytryptophan challenge (Meltzer *et al*, 1984). Serotonin abnormalities, like the cortisol response to chronic stress, may be seen as effects of depression. As Cowen points out in his commentary (Cowen, 2002), life events appear to increase fenfluramine responses only in the ‘depressed’ group. Fenfluramine responses were in fact lower ($P < 0.1$; Strickland *et al*, 2002: Fig. 1c) in the small number of depressed subjects without life-events. A small amount of serotonin release, induced by life events, playing onto super-sensitive 5-HT_{2C} receptors together with subsensitive autoreceptors, could account for the exaggerated serotonin responses to life events in the ‘depressed’ group. If so, then biological vulnerability to depression could involve an underlying presynaptic impairment of serotonin function. On this interpretation, some of the symptoms of depression, such as anxiety, might still be mediated by unstable excessive stimulation of 5-HT_{2C} receptors together with impaired 5-HT_{1A} resilience mechanisms as suggested by Deakin & Graeff (1991). Dr Moore's suggestion that resistance to depression in the face of life events might be mediated by normal or enhanced serotonin responsiveness is compatible with this line of reasoning. However, his suggestion that life events act on a vulnerable serotonin system through cortisol responses is not compatible with our evidence – depression in the community is not associated with hypercortisolaemia.

Declaration of interest

The research conducted was funded by the Wellcome Trust.

Cowen, P. J. (2002) Cortisol, serotonin and depression: all stressed out? *British Journal of Psychiatry*, **180**, 99–100.

Deakin, J. F. & Graeff, F. G. (1991) 5-HT and mechanisms of defence. *Journal of Psychopharmacology*, **5**, 305–315.

Maes, M., Calabrese, J. & Meltzer, H. Y. (1994) The relevance of the in- versus outpatient status for studies on HPA-axis in depression: spontaneous hypercortisolism is a feature of major depressed inpatients and not of major depression per se. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **18**, 503–517.

Meltzer, H. Y., Umberkoman, W. B., Robertson, A., et al (1984) Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. I. Enhanced response in depression and mania. *Archives of General Psychiatry*, **41**, 366–374.

Stokes, P. E., Stoll, P. M., Koslow, S. H., et al (1984) Pretreatment DST and hypothalamic–pituitary–adrenocortical function in depressed patients and comparison groups. A multicentre study. *Archives of General Psychiatry*, **41**, 257–267.

Strickland, P. J., Deakin, J. F. W., Percival, C., et al (2002) Bio-social origins of depression in the community. Interaction between social adversity, cortisol and serotonin neurotransmission. *British Journal of Psychiatry*, **180**, 168–173.

P. Strickland, J. F. W. Deakin Neuroscience and Psychiatry Unit, Stopford Building, School of Psychiatry and Behavioural Sciences, University of Manchester, Oxford Road, Manchester M13 9PT, UK

Non-right-handedness and schizophrenia

Sommer *et al* (2001: p. 349) found ‘compelling evidence . . . for decreased cerebral dominance in schizophrenia’, from a review of studies of handedness and other functional and anatomical asymmetries, consistent with the theory that schizophrenia is associated with an anomaly of the mechanisms of cerebral dominance (Crow, 1997), possibly a ‘right-shift factor’. They suggested that reduced asymmetry may help identify risk for schizophrenia. Procopio (2001) welcomed the review but cautioned that the ‘right shift’ is only a hypothesis and that findings for asymmetry in twins demonstrate an important environmental component.

The Sommer *et al* review puts it beyond doubt, in my opinion, that asymmetries are reduced in schizophrenia but this needs careful interpretation. The right-shift theory (for review see Annett, 2002) suggests that the main agent of asymmetry is environmental, random accidents of early growth in bilaterally symmetrical creatures. Random accidents occur in monozygotic twins as individuals, just as in other individuals. What is interesting about humans is that several chance distributions

of asymmetry are shifted in typical directions when the hypothesised RS+ gene is present. The gene may be absent, or when present its expression may be reduced by factors that influence early growth. Among the variables associated with reduction in the shift of the chance distribution for handedness are male gender, twinning, low birth weight, poor phonological processing (occurs in many people with dyslexia) and early brain lesions. These reductions must be detected against a base rate of non-right-handedness in about one-third of the general population. Differences in asymmetry are not causal, but rather the results of changes in the frequency or expression of the RS+ gene. They are not likely to be useful markers for any specific clinical disorder.

In schizophrenia, I have suggested that the gene may lose its directional coding and become 'agnostic' for right or left. Symptoms of schizophrenia are hypothesised to occur when speech cortex is impaired on both sides of the brain, as expected in 50% of the relevant genotypes. Until the RS+ gene and its variants are found, however, the theory remains a hypothesis.

Annett, M. (2002) *Handedness and Brain Asymmetry: The Right Shift Theory*. Hove: Psychology Press.

Crow, T. J. (1997) Schizophrenia as a failure of hemispheric dominance for language. *Trends in Neurosciences*, **20**, 339–343.

Procopio, M. (2001) Handedness and schizophrenia: genetic and environmental factors. *British Journal of Psychiatry*, **179**, 75–76.

Sommer, I., Aleman, A., Ramsey, N., et al (2001) Handedness, language lateralisation and anatomical asymmetry in schizophrenia. Meta-analysis. *British Journal of Psychiatry*, **178**, 344–351.

M. Annett School of Psychology, University of Leicester, University Road, Leicester LE1 7RH, UK

Genetic variation in European suicide rates

The fact that Hungary and Finland had among the highest reported suicide rates in Europe has led to speculations about the possible involvement of a common genetic factor in this phenomenon (Marušić & Farmer, 2001). Both Finns and Hungarians, as some linguists believe, belong to the Finno-Ugrian family of ethnic groups, with certain similarities in their ancient language. The high suicide rates in the various groups of Finno-Ugrians

Table 1 Allelic distribution of serotonergic gene polymorphisms in selected populations

Population	5-HT transporter gene S/L polymorphism		TPH gene 218 A/C polymorphism	
	S allele (%)	L allele (%)	Allele A (%)	Allele C (%)
Hungarian	48.8	51.2	46.4	53.6
Finnish	33.0	67.0	35.0	65.0
British	45.6	54.4	39.1	60.9

5-HT, serotonin; TPH, tryptophan hydroxylase.

suggested to Kondrichin (1995) that 'during the early stages of Finno-Ugrian ethnogenesis certain behavioural traits predisposing to suicide became fixed in the gene pool'.

We (Hrdina & Faludi, 2001) have examined the available molecular genetic data on serotonergic candidate genes and their allelic association with suicide (Nielsen *et al*, 1994; Du *et al*, 2000) for any similarities or differences in allelic frequencies between the various populations, particularly between Finns and Hungarians. A direct comparison between the findings of association between serotonergic gene polymorphism and suicidal behaviour is difficult, since in the reports of positive associations different phenotypes (suicide attempt, completed suicide) were investigated. However, if certain serotonergic gene variants increase the disposition for, or vulnerability to, suicide in some populations that share higher rates of suicide and that may share some similarities in their ethno-historical origins, then the frequency of these predisposing gene variants should be comparable in those populations.

Table 1 summarises the allelic distributions of serotonergic gene polymorphisms in some selected populations. It is clearly apparent that the allelic distributions of the two polymorphisms (5-HT transporter S/L polymorphism and tryptophan hydroxylase gene 218 A/C polymorphism) are remarkably different in Hungarian and Finnish populations. In fact, the frequencies of the S and L alleles of the 5-HT transporter in the Hungarian subjects are closer to those found in the British population.

The limited scientific evidence so far would suggest that there is no Finno-Ugrian 'suicide gene' or a shared genetic risk factor. It is unlikely that such a complex

phenomenon as suicidal behaviour is genetically determined by a single gene or even a few gene variants. A more likely scenario is that the genetic contribution to suicide will be represented by small size effects of many gene variants associated with processes involved in suicidal behaviour, and by interaction of these genetic factors with environmental ones.

Du, L., Faludi, G., Palkovits, M., et al (2000)

Tryptophan hydroxylase gene 218A/C polymorphism is not associated with depressed suicide. *International Journal of Neuropsychopharmacology*, **3**, 215–220.

Hrdina, P. & Faludi, G. (2001) Of suicide and genes. *Neuropsychopharmacologia Hungarica*, **3**, 53–58.

Kondrichin, S.V. (1995) Suicide among Finno-Ugrians. *Lancet*, **346**, 1632–1633.

Marušić, A. & Farmer, A. (2001) Genetic risk factors as possible causes of the variation in European suicide rates. *British Journal of Psychiatry*, **179**, 194–196.

Nielsen, D. A., Goldman, D., Virkkunen, M., et al (1994) Suicidality and 5-hydroxyindoleacetic acid concentration associated with tryptophan hydroxylase polymorphism. *Archives of General Psychiatry*, **51**, 34–38.

P. Hrdina Institute of Mental Health Research at Royal Ottawa Hospital, 1145 Carling Avenue, Ottawa, Canada K1Z 7K4

Chronic fatigue syndrome or neurasthenia?

The interesting study reported by Hickie *et al* (2002) draws attention to the prevalence of ICD-10 neurasthenia (World Health Organization, 1992) in a large sample of the Australian general population. The authors' findings are of the utmost importance for clinicians concerned with the disabling effects of fatigue but also provide food for thought in the wake of the CFS/ME Working Group (2002) report to the Chief Medical Officer. In this report, the term chronic fatigue syndrome/myalgic